FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4281667284> ?p ?o ?g. }

• W4281667284 endingPage "adv00756" @default.
• W4281667284 startingPage "adv00756" @default.
• W4281667284 abstract "Anti-PD-1 antibodies (Abs) are among the optimal adjuvant therapies for melanoma at high risk of recurrence, especially BRAF wild-type melanoma, but the anti-tumour effects of anti-PD-1 Abs in the adjuvant setting for acral melanoma have not been evaluated previously. The aim of this study was to analyse the efficacy and safety profiles of anti-PD-1 Ab monotherapy in the adjuvant setting in an Asian population including a high ratio of acral melanoma. The efficacy and safety profiles of anti-PD-1 Ab monotherapy in the adjuvant setting were retrospectively analysed in 78 Japanese patients with advanced melanoma, including 31 cases (40%) of acral melanoma. Overall relapse-free survival was 60.3% (47 of 78 cases, 95% confidence interval (CI) 49.2–70.4%), and 39.7% of patients (31 of 78 patients, 95% CI 29.6–50.8%) relapsed during the adjuvant PD-1 Ab treatment. Six cases (7.9%) discontinued the protocol due to serious adverse events. One case (1.3%) discontinued the protocol due to trauma. The relapse-free survival of acral melanoma was 25.8%, whereas that of high cumulative sun damage was 60.0%, and that of low cumulative sun damage was 57.1%. The acral type had a significantly lower 12-month relapse-free survival than other cutaneous types (p = 0.029). The acral type appeared to be an independent prognostic factor on multivariate analysis (p = 0.015). Adverse events due to anti-PD-1 antibody were observed in 37.1% overall. The results of this study suggest that anti-PD-1 Ab therapy in the adjuvant setting is less effective for acral melanoma than for other cutaneous types." @default.
• W4281667284 created "2022-06-13" @default.
• W4281667284 creator A5002901596 @default.
• W4281667284 creator A5004693750 @default.
• W4281667284 creator A5012462832 @default.
• W4281667284 creator A5012794894 @default.
• W4281667284 creator A5014048733 @default.
• W4281667284 creator A5017302973 @default.
• W4281667284 creator A5024945765 @default.
• W4281667284 creator A5031821817 @default.
• W4281667284 creator A5036690910 @default.
• W4281667284 creator A5036766499 @default.
• W4281667284 creator A5039882708 @default.
• W4281667284 creator A5040719027 @default.
• W4281667284 creator A5052637717 @default.
• W4281667284 creator A5069324961 @default.
• W4281667284 creator A5073959767 @default.
• W4281667284 date "2022-08-11" @default.
• W4281667284 modified "2023-10-14" @default.
• W4281667284 title "Adjuvant Anti-PD-1 Antibody Therapy for Advanced Melanoma: A Multicentre Study of 78 Japanese Cases" @default.
• W4281667284 cites W2166662937 @default.
• W4281667284 cites W2175744972 @default.
• W4281667284 cites W2295795165 @default.
• W4281667284 cites W2514381804 @default.
• W4281667284 cites W2572174216 @default.
• W4281667284 cites W2611187032 @default.
• W4281667284 cites W2621161007 @default.
• W4281667284 cites W2762347490 @default.
• W4281667284 cites W2770795622 @default.
• W4281667284 cites W2795035720 @default.
• W4281667284 cites W2797309423 @default.
• W4281667284 cites W2911806009 @default.
• W4281667284 cites W2912374321 @default.
• W4281667284 cites W2953195159 @default.
• W4281667284 cites W2957955537 @default.
• W4281667284 cites W2973186721 @default.
• W4281667284 cites W2990689300 @default.
• W4281667284 cites W3033948992 @default.
• W4281667284 cites W3086309329 @default.
• W4281667284 cites W3087697977 @default.
• W4281667284 cites W3171006409 @default.
• W4281667284 cites W3186496045 @default.
• W4281667284 cites W3199948887 @default.
• W4281667284 doi "https://doi.org/10.2340/actadv.v102.678" @default.
• W4281667284 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35670329" @default.
• W4281667284 hasPublicationYear "2022" @default.
• W4281667284 type Work @default.
• W4281667284 citedByCount "4" @default.
• W4281667284 countsByYear W42816672842022 @default.
• W4281667284 countsByYear W42816672842023 @default.
• W4281667284 crossrefType "journal-article" @default.
• W4281667284 hasAuthorship W4281667284A5002901596 @default.
• W4281667284 hasAuthorship W4281667284A5004693750 @default.
• W4281667284 hasAuthorship W4281667284A5012462832 @default.
• W4281667284 hasAuthorship W4281667284A5012794894 @default.
• W4281667284 hasAuthorship W4281667284A5014048733 @default.
• W4281667284 hasAuthorship W4281667284A5017302973 @default.
• W4281667284 hasAuthorship W4281667284A5024945765 @default.
• W4281667284 hasAuthorship W4281667284A5031821817 @default.
• W4281667284 hasAuthorship W4281667284A5036690910 @default.
• W4281667284 hasAuthorship W4281667284A5036766499 @default.
• W4281667284 hasAuthorship W4281667284A5039882708 @default.
• W4281667284 hasAuthorship W4281667284A5040719027 @default.
• W4281667284 hasAuthorship W4281667284A5052637717 @default.
• W4281667284 hasAuthorship W4281667284A5069324961 @default.
• W4281667284 hasAuthorship W4281667284A5073959767 @default.
• W4281667284 hasBestOaLocation W42816672841 @default.
• W4281667284 hasConcept C121608353 @default.
• W4281667284 hasConcept C126322002 @default.
• W4281667284 hasConcept C143998085 @default.
• W4281667284 hasConcept C16005928 @default.
• W4281667284 hasConcept C197934379 @default.
• W4281667284 hasConcept C2777658100 @default.
• W4281667284 hasConcept C2777863537 @default.
• W4281667284 hasConcept C2777982462 @default.
• W4281667284 hasConcept C2908647359 @default.
• W4281667284 hasConcept C38180746 @default.
• W4281667284 hasConcept C44249647 @default.
• W4281667284 hasConcept C502942594 @default.
• W4281667284 hasConcept C71924100 @default.
• W4281667284 hasConcept C90924648 @default.
• W4281667284 hasConcept C99454951 @default.
• W4281667284 hasConceptScore W4281667284C121608353 @default.
• W4281667284 hasConceptScore W4281667284C126322002 @default.
• W4281667284 hasConceptScore W4281667284C143998085 @default.
• W4281667284 hasConceptScore W4281667284C16005928 @default.
• W4281667284 hasConceptScore W4281667284C197934379 @default.
• W4281667284 hasConceptScore W4281667284C2777658100 @default.
• W4281667284 hasConceptScore W4281667284C2777863537 @default.
• W4281667284 hasConceptScore W4281667284C2777982462 @default.
• W4281667284 hasConceptScore W4281667284C2908647359 @default.
• W4281667284 hasConceptScore W4281667284C38180746 @default.
• W4281667284 hasConceptScore W4281667284C44249647 @default.
• W4281667284 hasConceptScore W4281667284C502942594 @default.
• W4281667284 hasConceptScore W4281667284C71924100 @default.
• W4281667284 hasConceptScore W4281667284C90924648 @default.
• W4281667284 hasConceptScore W4281667284C99454951 @default.
• W4281667284 hasLocation W42816672841 @default.

• next